Cytosorbents Corp CTSO

Healthcare SIC 3841 - Surgical & Medical Instruments & Apparatus NAICS Manufacturing › Miscellaneous Manufacturing › Medical Equipment and Supplies Manufacturing › Surgical and Medical Instrument Manufacturing derived Nasdaq

We are a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. CytoSorbents' proprietary blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Cartridges filled with these beads can be used with standard blood pumps already in the hospital (e.g. dialysis, continuous renal replacement therapy or CRRT, extracorporeal membrane oxygenation or ECMO, and heart-lung machines), where blood is repeatedly recirculated outside the body, through our cartridges where toxic substances are removed, and then back into the body. CytoSorbents' technologies are used in a number of broad applications. Specifically, two important applications are 1) the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and 2) the removal of inflammatory agents and toxins in common critical illnesses that can lead to massive inflammation, organ failure and patient death. The breadth of these critical illnesses include, for example, sepsis, burn injury, trauma, lung injury, liver failure, cytokine release syndrome, and pancreatitis as well as the removal of liver toxins that accumulate in acute liver dysfunction or failure, and the removal of myoglobin in severe rhabdomyolysis that can otherwise lead to renal failure. In these diseases, the risk of death can be extremely high, and there are few, if any, effective treatments.

Last close 5.27 2026-10-23
Market cap $331.2M 2026-06-30 share count
52-week range 0.30 - 7.44

Valuation FY2025 figures against the last close

P/S8.9x
P/E—
P/FCF—
EV/EBITDA—
Dividend yield—
Diluted EPS-0.13

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $37.1M$35.6M$31.1M$34.7M$43.2M$41.0M$24.9M$22.5M$15.2M$8.2M
Cost of revenue $10.6M$10.7M$9.1M$14.0M$11.0M$11.1M$7.4M$7.5M$5.5M$4.0M
Gross profit $26.5M$24.9M$22.0M$20.7M$32.1M$30.0M$17.6M$15.0M$9.6M$5.6M
R&D ——$15.7M$15.1M$16.4M$8.8M$12.1M$7.7M$3.2M$4.1M
SG&A $35.6M$33.7M$38.3M$34.3M$35.8M$28.5M$22.0M$20.9M$14.9M$11.8M
Total operating expenses $41.2M$41.3M$53.9M$52.3M$54.9M$40.3M$36.6M$30.6M$19.5M$17.1M
Operating income -$14.7M-$16.5M-$31.9M-$31.5M-$22.7M-$10.4M-$19.0M-$15.6M-$9.8M-$11.5M
Pre-tax income -$8.6M-$22.4M-$30.1M-$33.9M-$25.3M-$9.0M-$20.4M-$17.8M-$9.1M-$12.1M
Income tax $401.0K$1.7M$813.7K$1.1M$736.0K$1.1M$1.1M$619.5K$676.7K$318.6K
Net income -$8.2M-$20.7M-$29.2M-$32.8M-$24.6M-$7.8M-$19.3M-$17.2M-$8.5M-$11.8M
EPS, basic -0.13-0.38-0.65-0.75-0.57-0.20-0.60———
EPS, diluted -0.13-0.38-0.65-0.75-0.57-0.20-0.60-0.56-0.32-0.46
Shares, diluted (wtd. avg.) 62.2M54.4M44.7M43.6M43.4M38.8M32.3M———

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $6.2M$3.3M$15.6M$23.8M$53.8M$71.4M$12.2M$22.4M$17.3M$5.2M
Short-term investments —————————$0
Receivables $7.5M$7.3M$6.1M$5.7M$4.5M$5.2M$4.5M$3.9M$2.2M$1.4M
Inventory $5.3M$2.7M$2.0M$1.7M$4.8M$2.7M$2.1M$833.1K$795.7K$834.0K
Total current assets $20.6M$21.6M$23.6M$28.2M$64.3M$82.5M$20.9M$28.3M$20.7M$7.8M
Property, plant and equipment $7.8M$9.0M$10.1M$10.7M$5.2M$2.1M$1.9M$1.7M$1.4M$569.4K
Other intangibles $3.2M$3.7M$3.9M$4.4M$4.7M$4.2M$3.4M$2.6M$1.8M—
Total assets $44.2M$47.4M$52.4M$57.5M$89.5M$90.0M$27.4M$34.2M$24.1M$9.7M
Accounts payable $2.9M$3.3M$3.8M$1.7M$2.8M$1.8M$2.0M$1.5M$1.2M$1.3M
Short-term debt ——$2.5M——$0$1.7M$666.7K$4.0M$833.3K
Total current liabilities $9.7M$9.8M$10.0M$9.5M$13.7M$10.2M$9.9M$6.9M$7.8M$4.3M
Long-term debt $16.7M$14.0M$2.5M$5.0M—$0$13.4M$9.3M$6.0M$4.1M
Total liabilities $38.3M$36.3M$28.0M$27.5M$26.9M$10.7M$24.0M$17.3M$13.8M$8.4M
Retained earnings -$312.2M-$304.0M-$268.0M-$261.4M-$221.2M-$196.6M-$188.8M-$169.5M-$152.3M-$143.5M
Total equity $5.9M$11.1M$23.5M$35.4M$62.6M$79.2M$3.4M$16.9M$10.3M$1.3M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow -$12.4M-$14.4M-$21.7M-$28.2M-$14.0M-$5.6M-$16.8M-$10.8M-$6.5M-$6.7M
Depreciation and amortisation $1.2M$1.3M$1.2M$688.6K$571.2K$553.9K$495.7K$329.5K$177.8K$126.1K
Stock-based compensation $2.8M$3.8M$4.2M$3.4M$4.0M$3.5M$1.7M$4.4M$3.3M$2.8M
Capital expenditure $164.0K$284.0K$538.1K$6.1M$3.6M$708.4K$698.2K$672.0K$990.7K$140.7K
Investing cash flow -$415.0K-$669.0K-$936.2K-$6.5M-$4.3M-$1.7M-$1.5M-$1.5M-$1.7M$1.6M
Financing cash flow $9.3M$9.3M$14.5M$5.0M$715.2K$66.3M$8.2M$17.5M$20.1M$5.1M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-077798.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -40M -20M 0 20M 40M 60M Revenue, FY2016: 8.2M Gross profit, FY2016: 5.6M Net income, FY2016: -11.8M Revenue, FY2017: 15.2M Gross profit, FY2017: 9.6M Net income, FY2017: -8.5M Revenue, FY2018: 22.5M Gross profit, FY2018: 15M Net income, FY2018: -17.2M Revenue, FY2019: 24.9M Gross profit, FY2019: 17.6M Net income, FY2019: -19.3M Revenue, FY2020: 41M Gross profit, FY2020: 30M Net income, FY2020: -7.8M Revenue, FY2021: 43.2M Gross profit, FY2021: 32.1M Net income, FY2021: -24.6M Revenue, FY2022: 34.7M Gross profit, FY2022: 20.7M Net income, FY2022: -32.8M Revenue, FY2023: 31.1M Gross profit, FY2023: 22M Net income, FY2023: -29.2M Revenue, FY2024: 35.6M Gross profit, FY2024: 24.9M Net income, FY2024: -20.7M Revenue, FY2025: 37.1M Gross profit, FY2025: 26.5M Net income, FY2025: -8.2M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $8.2M $15.2M $22.5M $24.9M $41.0M $43.2M $34.7M $31.1M $35.6M $37.1M
Gross profit $5.6M $9.6M $15.0M $17.6M $30.0M $32.1M $20.7M $22.0M $24.9M $26.5M
Net income -$11.8M -$8.5M -$17.2M -$19.3M -$7.8M -$24.6M -$32.8M -$29.2M -$20.7M -$8.2M

Recent filings and events

  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Delisting notice Item 3.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Regulation FD disclosure Item 7.01
  • Results announced Item 2.02
  • Delisting notice Item 3.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 3841

TickerCompanyMarket capP/ERevenue growth
SYK STRYKER CORP $117.81B 36.6x 11.2%
MMM 3M CO $89.46B 28.9x 1.5%
BSX BOSTON SCIENTIFIC CORP $66.22B 23.6x 19.9%
BDX BECTON DICKINSON & CO $54.18B 34.2x 8.2%
RMD RESMED INC $36.48B 24.2x 9.9%
DXCM DEXCOM INC $29.41B 37.3x 15.6%
MDLN Medline Inc. $29.20B — 11.5%
WST WEST PHARMACEUTICAL SERVICES INC $27.60B 57.8x 6.3%